Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
### Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. It may also be used for other seizure types, often in refractory cases.
### Adult Dosing
* **Lennox-Gastaut Syndrome (LGS) Adjunctive Therapy:**
* Initiate at 5 mg twice daily.
* Titrate dose, not more frequently than weekly, to a target dose of 10 mg twice daily.
* Maximum recommended dose: 20 mg twice daily (40 mg/day).
* **Other Seizure Types:** Dosing varies significantly based on indication and patient response. Consult specific guidelines or institutional protocols.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) Adjunctive Therapy (2 years and older):**
* **2 to <10 years:**
* Initiate at 5 mg once daily.
* Titrate dose, not more frequently than weekly, to a target dose of 5 mg twice daily.
* Maximum recommended dose: 10 mg twice daily (20 mg/day).
* **10 years and older:** Dosing is the same as for adults (initially 5 mg twice daily, titrate to 10 mg twice daily, max 40 mg/day).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Specific dose adjustments are not well-defined, but lower starting doses and slower titration may be prudent.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but monitor for increased CNS effects.
* **Concomitant Medications:** Consider potential interactions (see Key Drug Interactions).
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory depression.
* Severe hepatic insufficiency.
### Adverse Effects
* **Common:** Drowsiness, somnolence, constipation, decreased appetite, fatigue, irritability, aggression, behavior problems, upper respiratory tract infections.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, withdrawal symptoms, dependence.
### Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depression. Avoid concomitant use or use with extreme caution, monitoring closely for respiratory depression and sedation.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Inhibitors (e.g., ketoconazole, ritonavir) can increase clobazam levels. Inducers (e.g., rifampin, carbamazepine) can decrease clobazam levels.
* **Other Antiepileptic Drugs (AEDs):** Monitor for altered clobazam or AED levels and efficacy. Phenytoin, primidone, and phenobarbital may affect clobazam metabolism. Clobazam may affect levels of other AEDs.
### Monitoring
* **Efficacy:** Assess seizure frequency and severity.
* **Safety:** Monitor for sedation, cognitive impairment, behavioral changes, respiratory status, and signs of withdrawal.
* **Suicidal Behavior/Ideation:** Screen for and monitor suicidal thoughts and behaviors.
* **Skin Reactions:** Educate patients on signs/symptoms of severe skin reactions.
* **Concomitant Medications:** Monitor for drug interactions.
### Clinical Pearls
* Clobazam should be initiated at a low dose and titrated slowly to minimize adverse effects, particularly sedation and behavioral changes.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering of the dose is recommended when discontinuing therapy.
* Due to the risk of serious skin reactions, patients should be advised to seek immediate medical attention if a rash develops.
* Clobazam is a Schedule IV controlled substance.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and institutional protocols before making any clinical decisions.*
